# Citation Report

List of articles citing

## Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration

DOI: 10.1634/theoncologist.2012-0235
Oncologist, 2013, 18, 104-11.

| # | Paper | IF | Citations |
|---|---|---|---|
| 31 | NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl) : a model for stromal cell-tumor cell interaction for human colon cancer. *Digestive Diseases and Sciences*, **2014**, 59, 1169-79 | 4 | 41 |
| 30 | Discrepancies in drug approvals: A global dilemma. *Cancer*, **2015**, 121, 3360-1 | 6.4 | 1 |
| 29 | Outcomes and endpoints in cancer trials: bridging the divide. *Lancet Oncology, The*, **2015**, 16, e43-52 | 21.7 | 56 |
| 28 | Outcomes and endpoints in trials of cancer treatment: the past, present, and future. *Lancet Oncology, The*, **2015**, 16, e32-42 | 21.7 | 111 |
| 27 | Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency. *Annals of Oncology*, **2015**, 26, 211-216 | 10.3 | 15 |
| 26 | The Relationship Between Development Start Lag and Approval Lag in Oncology Drug Development in Japan. *Therapeutic Innovation and Regulatory Science*, **2015**, 49, 911-919 | 1.2 | 7 |
| 25 | Challenges in translating endpoints from trials to observational cohort studies in oncology. *Clinical Epidemiology*, **2016**, 8, 195-200 | 5.9 | 8 |
| 24 | Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis. *Oncologist*, **2016**, 21, 487-93 | 5.7 | 13 |
| 23 | Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure. *Health Affairs*, **2016**, 35, 805-12 | 7 | 46 |
| 22 | Practical Considerations for Clinical Pharmacology in Drug Development: A Survey of 44 FDA Oncology Approvals. **2016**, 237-301 | | 1 |
| 21 | Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting. *Journal of Clinical Oncology*, **2016**, 34, 1469-75 | 2.2 | 27 |
| 20 | Modeling timelines for translational science in cancer; the impact of technological maturation. *PLoS ONE*, **2017**, 12, e0174538 | 3.7 | 9 |
| 19 | Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion. **2017**, | | 0 |
| 18 | Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials. *Hematological Oncology*, **2018**, 36, 547 | 1.3 | 8 |
| 17 | Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits. *Expert Opinion on Investigational Drugs*, **2018**, 27, 155-162 | 5.9 | 19 |
| 16 | Local Control and Toxicity of External Beam Reirradiation With a Pulsed Low-dose-rate Technique. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 959-964 | 4 | 5 |
| 15 | Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials. *Hematological Oncology*, **2018**, 36, 37-43 | 1.3 | 13 |

| | | | |
|---|---|---|---|
| 14 | The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. *Trials*, **2018**, 19, 505 | 2.8 | 5 |
| 13 | Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies. *Journal of Clinical Epidemiology*, **2019**, 114, 49-59 | 5.7 | 13 |
| 12 | Medicinal Plants from Brazilian Cerrado: Antioxidant and Anticancer Potential and Protection against Chemotherapy Toxicity. *Oxidative Medicine and Cellular Longevity*, **2019**, 2019, 3685264 | 6.7 | 9 |
| 11 | Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer. *Advances in Therapy*, **2019**, 36, 2122-2136 | 4.1 | 54 |
| 10 | Health Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion. *American Journal of Health Economics*, **2019**, 5, 360-375 | 1.8 | |
| 9 | REFLECTIONS AND PERSPECTIVES ON BIOSIMILARS IN BRAZIL. *International Journal of Pharmacy and Pharmaceutical Sciences*, **2020**, 26-31 | 0.3 | |
| 8 | Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer. *European Journal of Cancer*, **2021**, 151, 221-232 | 7.5 | 2 |
| 7 | Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation. *Clinical Oncology*, **2021**, | 2.8 | 1 |
| 6 | Generating real-world tumor burden endpoints from electronic health record data: Comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer. | | |
| 5 | Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials. *Korean Journal of Radiology*, **2020**, 21, 471-482 | 6.9 | 1 |
| 4 | Availability of biological cancer drugs under research: registration and price in Brazil, Colombia, and Mexico. *Physis*, **2020**, 30, | 0.8 | |
| 3 | Clinical endpoints in oncology - a primer. *American Journal of Cancer Research*, **2021**, 11, 1121-1131 | 4.4 | 1 |
| 2 | Review of Clinical Equipoise: Examples from Oncology Trials.. *Current Reviews in Clinical and Experimental Pharmacology*, **2021**, | | |
| 1 | Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review. *Journal of Health Politics, Policy and Law*, **2022**, | 2.6 | 0 |